高危非致残性缺血性脑血管事件溶栓治疗的研究进展  

Research Progress in Thrombolytic Therapy of High Risk Non-Disabling Ischemic Cerebrovascular Events

作　　者：武玉琳 满君 彭倩 韩刚[1] WU Yulin;MAN Jun;PENG Qian;HAN Gang(Department Two of Encephalopathy,Dongfang Hospital,Beijing University of Chinese Medicine,Beijing 100078,China)

机构地区：[1]北京中医药大学东方医院脑病二科,北京100078

出　　处：《医学综述》2018年第17期3424-3429,共6页Medical Recapitulate

摘　　要：目前对急性脑梗死早期或超早期溶栓治疗越来越普遍,其疗效得到临床工作者及患者的肯定。高危非致残性缺血性脑血管事件(HR-NICE)发病后不遗留明显残疾,看似症状轻微或迅速好转,容易被临床工作者忽视而未采取积极的治疗方式,导致病情加重或复发,预后不良。近年来研究表明,溶栓治疗HR-NICE可使患者获益并改善预后,但其安全性也存在争议。影响HR-NICE患者预后的因素较多,有效识别预后不良的因素,采取安全有效的治疗方式,合理筛选溶栓人群,改善HR-NICE患者预后,成为当前研究的热点。Thrombolytic therapy for acute ischemic stroke is becoming more and more common as its curative effect has been confirmed by the clinical workers and patients.High risk non-disabling ischemic cerebrovascular events（HR-NICE）do not cause obvious disabilities,which seem to be featured with mild or rapidly improving symptoms,and are easily neglected by the clinical workers,as such patients do not receive timely treatment resulting in disease aggravation,recurrence and poor prognosis.In recent years,increasing researches have shown that thrombolysis of HR-NICE could benefit the patients and improve the prognosis,though the safety of thrombolytic therapy remains controversial.There are many factors that can affect the prognosis of HR-NICE patients.Hence,identifying relevant factors,adopting a safe and effective treatment and relevant patient screening in hope to improve the prognosis of HR-NICE patients have become the hotspots in the research field.

关 键 词：高危非致残 轻型卒中 溶栓 预后 安全性 

分 类 号：R743.3[医药卫生—神经病学与精神病学]